| Literature DB >> 29367187 |
Delphine Carli1,2, Guillaume Fahrni3, Pascal Bonnabry1,2, Christian Lovis3,4.
Abstract
BACKGROUND: Computerized decision support systems have raised a lot of hopes and expectations in the field of order entry. Although there are numerous studies reporting positive impacts, concerns are increasingly high about alert fatigue and effective impacts of these systems. One of the root causes of fatigue alert reported is the low clinical relevance of these alerts.Entities:
Keywords: decision support systems, clinical; medical order entry systems; predictive value of tests; sensitivity; specificity; system, medication alert
Year: 2018 PMID: 29367187 PMCID: PMC5803531 DOI: 10.2196/medinform.7170
Source DB: PubMed Journal: JMIR Med Inform
Figure 1Flowchart describing the systematic literature review process.
Characteristics of the studies included in the paper.
| Source | Study design | Study period | Study site | Specialty | Patient care | Number of patients with an alert |
| Riggio et al, 2008 [ | Control and intervention | 3 weeks | 728-bed hospital | Medicine, surgery, pediatric | Inpatient | Control group: 47; |
| Cash, 2009 [ | Retrospective analysis | N/Aa | Hospital | Pediatric | Inpatient | N/A |
| Van der Sijs et al, 2010 [ | Control/intervention | 1 month | 807-bed hospital | N/A | Inpatient | N/A |
| FitzHenry et al, 2011 [ | Retrospective analysis | 7 months | 807-bed hospital | N/A | Inpatient | 2404 |
| Eppenga et al, 2014 [ | Cross-sectional | 5 days | 800-bed hospital | N/A | Inpatient | 619 |
| Moore et al, 2009 [ | Prospective observational | 5 months | 684-bed hospital | N/A | N/A | 456 |
| Fritz et al, 2012 [ | Prospective observational | N/A | 850-bed hospital | Internal medicine | Inpatient | 100 |
| Harinstein et al, 2012 [ | Prospective observational | 8 weeks | Medical center | Medical and cardiac intensive care | Inpatient | 64 |
| Zorina et al, 2012 [ | Cross-sectional | 1 year | 850-bed hospital | Neurological | Inpatient | 484 |
| Beeler et al, 2013 [ | Retrospective analysis | 90 weeks | 850-bed hospital | N/A | Inpatient | 922 |
| Rommers et al, 2013 [ | Prospective observational | 5 months | Hospital | Internal medicine, cardiology, lung, gastrointestinal, hematology | Inpatient | 931 |
| Stultz et al, 2013 [ | Retrospective analysis | 1 month | 350-bed hospital | Pediatric | Inpatient | 573 |
| Stultz et al, 2014 [ | Retrospective analysis | 1 month | 350-bed hospital | Pediatric | Inpatient | 189 |
| Dormann et al, 2004 [ | Prospective study/retrospective analysis | 6 months | Hospital | Gastroenterological | N/A | 377 |
| Raschke et al, 1998 [ | Prospective case | 6 months | 650-bed hospital | Nonobstetrics | N/A | 9306 |
| Silverman et al, 2004 [ | Retrospective analysis | 3 one-year periods | 726-bed teaching institution | Tertiary care | N/A | N/A |
| Handler et al, 2007 [ | Systematic review | 12 studies | Hospital | N/A | N/A | N/A |
aN/A: not applicable.
Characteristics of alerts included in the paper.
| Source | Alert notification | Alert origin | Alert target |
| Riggio et al, 2008 | Interruptive alert | — | Drug-lab interaction: heparin-induced thrombocytopenia |
| Cash, 2009 | Interruptive alert | — | Drug-drug interaction Drug-lab interaction Duplicate order Drug-dosage interaction Drug-allergy interaction |
| Van der Sijs et al, 2010 | Interruptive alert | Commercial system | Drug-dosage interaction: overdosage Drug-drug interaction Drug–dosage interaction Drug-allergy interaction Drug-pregnancy interaction: contraindication Duplicate order Drug-lab interaction: bad renal function Drug-pharmacogenetic interaction: poor metabolizer |
| FitzHenry et al, 2011 | Interruptive alert | — | Drug-dosage interaction: warfarin |
| Eppenga et al, 2014 | Interruptive alert | — | Basic Drug-drug interaction Duplicate order |
| Advanced Drug-drug interaction Drug-dosage interaction Drug-lab interaction Drug-lab interaction: missing laboratory value Drug-disease interaction Drug-age interaction | |||
| Moore et al, 2009 | — | — | Drug-lab interaction developing adverse drug event (ADE): hypoglycemia, hypokalemia, hyperkalemia, and thrombocytopenia |
| Fritz et al, 2012 | — | Commercial system | Drug-drug interaction |
| Harinstein et al, 2012 | — | Commercial system | Drug-lab interaction: drug-induced thrombocytopenia |
| Zorina et al, 2012 | — | Commercial system | Drug-drug interaction |
| Beeler et al, 2013 | Noninterruptive alert | — | Drug-drug interaction |
| Rommers et al, 2013 | — | — | Drug-lab interaction: ADE system |
| Stultz et al, 2013 | Interruptive alert | — | Drug-dosage interaction |
| Stultz et al, 2014 | Interruptive alert | — | Drug-dosage interaction |
| Dormann et al, 2003 | — | — | Drug-lab interaction: predicted ADE |
| Raschke et al, 1998 | — | — | Drug-monitoring interaction: predicted ADE Drug-age interaction: predicted ADE Drug-lab interaction: predicted ADE |
| Silverman et al, 2004 | — | — | ADE detection system Drug-allergy interaction Drug-drug interaction Therapeutic duplication Drug-dosage interaction Drug-lab interaction |
| Handler et al, 2007 | — | — | Antidote Drug-lab interaction Drug-dosage interaction: subtherapeutic medication levels |
Positive predictive value (PPV), sensitivity or specificty for studies included in the review.
| Source | Number of alerts | Positive predictive value (%) | Sensitivity (%) | Specificity (%) | False positive (%) |
| Riggio et al, 2008 | 41,922 | 2.3 | 87 | 87 | N/Aa |
| Cash, 2009 | — | 1.4 | N/A | N/A | N/A |
| Van der Sijs et al, 2010a | — | — | 38-79 (n=29) | 11-89 (n=19) | N/A |
| FitzHenry et al, 2011b | 2308 | — | N/A | N/A | 46-85 |
| Eppenga et al, 2014 | Basic 2607/advanced 2256 | Basic: 5.8 (n=150/2607)/advanced: 17 ( | N/A | N/A | N/A |
| Moore et al, 2009 | 611 | 4.0 (n=125)-31.2 (n=218) | N/A | N/A | N/A |
| Fritz et al, 2012 | 743 | 5.7 (n=3/53)-8 (n=29/362) | 9.1(n=3/53) -87.9 (n=29/362) | N/A | N/A |
| Harinstein et al, 2012 | 350 (204/12/134) | 36 (n=73/204)-83(n=10/12) | N/A | N/A | N/A |
| Zorina et al, 2012 | 1759/1082c | 24/48c | 70.6/72.4c | N/A | N/A |
| Beeler et al, 2013d | 7902 | 1.6 (n=47/2866) ( | N/A | N/A | N/A |
| Rommers et al, 2013 | 2650 (963/722/437) | 8 (n=204/2650) | N/A | N/A | N/A |
| Stultz et al, 2013e | 3774 | 13.8 | N/A | N/A | N/A |
| Stultz et al, 2014 | 257 | Odds ratio (OR) 8 (95% CI 6.8-9.3) | OR 60.3 (95% CI 54.0-66.3) | OR 96.2 (95% CI: 96.0-96.3) | N/A |
| Dormann et al, 2003 | 2328 (1748/580) | Prospective study 25(n=574/2328)(13-40)/retrospective analysis 32(18-67) | 91/40 | 23/76 | N/A |
| Raschke et al, 1998 | 1116 (803/313) | 24 (n=5/21)-97(n=190/196) | N/A | N/A | N/A |
| Silverman et al, 2004 | 3117/7390/6136 | 0-60 | N/A | N/A | N/A |
| Handler et al, 2007 | — | Antidotes: 9-11 | N/A | N/A | N/A |
| — | Laboratory test result: 3-27 | N/A | N/A | N/A | |
| Supratherapeutic medication levels: 3-50 | N/A | N/A | N/A |
aN/A: not applicable.
cNo PPV available.
cValues for two different programs of clinical decision support systems.
dPositive predictive value calculated for the review: PPV was defined as the quotient of the number of advice/interventions to prevent a possible adverse drug event and the total number of alerts generated.
ePPV calculated for the review: PPV was defined as number of correct alerts in comparison with Lexicomp.